MECHELEN, BELGIUM--(Marketwire -06/22/12)- Galapagos NV (GLPGF)announced today that it won the European Mediscience Awards forTransaction ofthe year and Chief Executive of the year at last night's ceremony inLondon. The Transaction of the year award recognizes the global collaborationwithAbbott for selective JAK1 inhibitor GLPG0634. The Chief Executive of theyearaward recognizes the leadership and other qualities demonstrated by Onnovan deStolpe.
"We are pleased to have won two European Mediscience awards, whichalsoacknowledge the efforts of the entire Galapagos team," said Dr RajParekh,Chairman of the Board of Directors of Galapagos. "Galapagos isexecuting itsstrategy to become a European leader in biotech, and these awardsrecognize theprogress Galapagos is making toward achieving that ambition."
About the European Mediscience Awards
The European Mediscience Awards have been held since 2002 and celebrate thebestin the quoted life science, healthcare and biotech industries. The eventhasgrown to be the largest annual gathering of private and publicly quotedhealthcare, biotech and life science companies in Europe, attracting over500attendees. More info at: www.mediscience-event.co.uk
Galapagos (GLPGF) (GLPYY) is a mid-sizebiotechnology companyspecialized in the discovery and development of small molecule and antibodytherapies with novel modes-of-action. The Company is progressing GLPG0634,aswell as one of the largest pipelines in biotech, with four programs indevelopment and over 30 discovery programs. The Galapagos Group has about800employees and operates facilities in six countries, with globalheadquarters inMechelen, Belgium. More info at: www.glpg.com
This release may contain forward-looking statements, including,withoutlimitation, statements containing the words "believes,""anticipates,""expects," "intends," "plans," "seeks," "estimates," "may," "will,""could,""stands to," and "continues," as well as similar expressions. Suchforward-looking statements may involve known and unknown risks,uncertainties and otherfactors which might cause the actual results, financial condition,performanceor achievements of Galapagos, or industry results, to be materiallydifferentfrom any historic or future results, financial conditions,performance orachievements expressed or implied by such forward-looking statements.Giventhese uncertainties, the reader is advised not to place any unduereliance onsuch forward-looking statements. These forward-looking statements speakonly asof the date of publication of this document. Galapagos expresslydisclaims anyobligation to update any such forward-looking statements in thisdocument toreflect any change in its expectations with regard thereto or anychange inevents, conditions or circumstances on which any such statement is based,unlessrequired by law or regulation.
This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE[HUG#1621438]
- Galapagos NV
Onno van de Stolpe
Tel: +31 6 2909 8028
Director Investor Relations
Tel: +31 6 2291 6240